1. MacPherson RD. New directions in pain management. Drugs of Today. 2002;38(2):135–145. [PubMed] 2. Dworkin RH. An overview of neuropathic pain: syndromes, symptoms, signs, and several mechanisms. Clinical Pain. 2002;18(6):343–349. [PubMed]
3. Turk DC, Okifuji A. Treatment of chronic pain patients: clinical outcomes, cost-effectiveness, and cost-benefits. Critical Reviews in Physical and Rehabilitation Medicine. 1998;10(2):181–208.
4. Breivik H. Opioids in cancer and chronic non-cancer pain therapy: indications and controversies. Acta Anaesthesiologica Scandinavica. 2001;45(9):1059–1066. [PubMed] 5. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. The Lancet. 1999;353(9168):1959–1964. [PubMed]
6. Siddall PJ, Yezierski RP, Loeser J. Pain following spinal cord injury: clinical features, prevalence, and taxonomy. IASP Newsletter. 2000;3:3–7.
7. Jain KK. Cell therapy for pain. Expert Opinion on Biological Therapy. 2008;8(12):1847–1853. [PubMed] 8. Jeon Y. Cell based therapy for the management of chronic pain. Korean Journal of Anesthesiology. 2011;60(1):3–7. [PMC free article] [PubMed] 9. Klass M, Gavrikov V, Drury D, et al. Intravenous mononuclear marrow cells reverse neuropathic pain from experimental mononeuropathy. Anesthesia and Analgesia. 2007;104(4):944–948. [PubMed]
10. Eaton MJ, Wolfe SQ, Widerstrom-Noga E. Stem Cell & Regenerative Medicine. Oak Park, Ill, USA: Bentham Science; 2010. Use of progenitor cells in pain management; pp. 94–128.
11. Eaton MJ, Sagen J. Cell therapy for models of pain and traumatic brain injury. In: Sanberg PR, Davis CD, editors. Cell Therapy for Brain Repair. Totowa, NJ, USA: The Humana Press; 2007. pp. 199–239.
12. Eaton M. Common animal models for spasticity and pain. Journal of Rehabilitation Research and Development. 2003;40(4):41–54. [PubMed] 13. Eaton MJ. Emerging cell and molecular strategies for the study and treatment of painful peripheral neuropathies. Journal of the Peripheral Nervous System. 2000;5(2):59–74. [PubMed] 14. Lazorthes Y, Sallerin B, Verdie JC, et al. Management of intractable cancer pain: from intrathecal morphine to chromaffin cell allograft. Neurochirurgie. 2000;46(5):454–465. [PubMed] 15. Wilson SP, Yeomans DC. Genetic therapy for pain management. Current Review of Pain. 2000;4(6):445–450. [PubMed] 16. Eaton MJ, Herman JP, Jullien N, Lopez TL, Martinez M, Huang J. Immortalized chromaffin cells disimmortalized with Cre/lox site-directed recombination for use in cell therapy for pain after partial nerve injury. Experimental Neurology. 2002;175(1):49–60. [PubMed] 17. Hottinger AF, Aebischer P. Treatment of diseases of the central nervous system using encapsulated cells. Advances and Technical Standards in Neurosurgery. 1999;25:3–20. [PubMed] 18. Widerström-Noga EG, Felipe-Cuervo E, Broton JG, Duncan RC, Yezierski RP. Perceived difficulty in dealing with consequences of spinal cord injury. Archives of Physical Medicine and Rehabilitation. 1999;80(5):580–586. [PubMed] 19. Siddall PJ. Management of neuropathic pain following spinal cord injury: now and in the future. Spinal Cord. 2009;47(5):352–359. [PubMed] 20. Siddall PJ, Taylor DA, McClelland JM, Rutkowski SB, Cousins MJ. Pain report and the relationship of pain to physical factors in the first 6 months following spinal cord injury. Pain. 1999;81(1-2):187–197. [PubMed]
21. Widerstrom-Noga E, Turk DC. Outcome measures in chronic pain trials involving people with spinal cord injury. SCI Psychosocial Process. 2004;17:258–267.
22. Hsieh ST. Pathology and functional diagnosis of small-fiber painful neuropathy. Acta Neurologica Taiwanica. 2010;19(2):82–89. [PubMed] 23. St.Onge ELS, Miller SA. Pain associated with diabetic peripheral neuropathy: a review of available treatments. Pharmacology and Therapeutics. 2008;33(3):166–179. [PMC free article] [PubMed] 24. Fischer TZ, Waxman SG. Neuropathic pain in diabetes-evidence for a central mechanism. Nature Reviews Neurology. 2010;6(8):462–466. [PubMed] 25. Berger JV, Knaepen L, Janssen SP, et al. Cellular and molecular insights into neuropathy-induced pain hypersensitivity for mechanism-based treatment approaches. Brain Research Reviews. 2011;67(1-2):282–310. [PubMed] 26. Roth T, van Seventer R, Murphy TK. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. Current Medical Research and Opinion. 2010;26(10):2411–2419. [PubMed] 27. Wu HH, Wilcox GL, McLoon SC. Implantation of AtT-20 or genetically modified AtT-20/hENK cells in mouse spinal cord induced antinociception and opioid tolerance. Journal of Neuroscience. 1994;14(8):4806–4814. [PubMed] 28. Eaton MJ, Karmally S, Martinez MA, Plunkett JA, Lopez T, Cejas PJ. Lumbar transplant of neurons genetically modified to secrete galanin reverse pain-like behaviors after partial sciatic nerve injury. Journal of the Peripheral Nervous System. 1999;4(3-4):245–257. [PubMed] 29. Eaton MJ, Santiago DI, Dancausse HA, Whittemore SR. Lumbar transplants of immortalized serotonergic neurons alleviate chronic neuropathic pain. Pain. 1997;72(1-2):59–69. [PubMed] 30. Eaton MJ, Plunkett JA, Martinez MA, et al. Transplants of neuronal cells bioengineered to synthesize GABA alleviate chronic neuropathic pain. Cell Transplantation. 1999;8(1):87–101. [PubMed] 31. Cejas PJ, Martinez M, Karmally S, et al. Lumbar transplant of neurons genetically modified to secrete brain-derived neurotrophic factor attenuates allodynia and hyperalgesia after sciatic nerve constriction. Pain. 2000;86(1-2):195–210. [PubMed]
32. Sagen J, Eaton MJ. Cellular implantation for the treatment of chronic pain. In: Schmidt WK, editor. pain: current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. New York, NY, USA: Marcel Dekker; 2003. pp. 815–833.
33. Eaton MJ. Cell and molecular approaches to the attenuation of pain after spinal cord injury. Journal of Neurotrauma. 2006;23(3-4):549–559. [PubMed] 34. Andrews PW, Damjanov I, Simon D. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation in vivo and in vitro. Laboratory Investigation. 1984;50(2):147–162. [PubMed] 35. Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Developmental Biology. 1984;103(2):285–293. [PubMed] 36. Borlongan CV, Tajima Y, Trojanowski JQ, Lee VMY, Sanberg PR. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Experimental Neurology. 1998;149(2):310–321. [PubMed] 37. Newman MB, Misiuta I, Willing AE, et al. Tumorigenicity issues of embryonic carcinoma-derived stem cells: relevance to surgical trials using NT2 and hNT neural cells. Stem Cells and Development. 2005;14(1):29–43. [PubMed] 38. Trojanowski JQ, Kleppner SR, Hartley RS, et al. Transfectable and transplantable postmitotic human neurons: a potential “platform” for gene therapy of nervous system diseases. Experimental Neurology. 1997;144(1):92–97. [PubMed] 39. Lee VMY, Hartley RS, Trojanowski JQ. Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: implications for improving therapy of spinal cord injury. Progress in Brain Research. 2000;128:299–307. [PubMed] 40. Hara K, Yasuhara T, Maki M, et al. Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke. Progress in Neurobiology. 2008;85(3):318–334. [PubMed] 41. Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 2000;55(4):565–569. [PubMed] 42. Yoshioka A, Yudkoff M, Pleasure D. Expression of glutamic acid decarboxylase during human neuronal differentiation: studies using the NTera-2 culture system. Brain Research. 1997;767(2):333–339. [PubMed] 43. Eaton MJ, Wolfe SQ, Martinez M, et al. Subarachnoid transplant of a human neuronal cell line attenuates chronic allodynia and hyperalgesia after excitotoxic SCI in the rat. Pain. 2007;8(1):33–50. [PubMed] 44. Wolfe SQ, Garg M, Cumberbatch NMA, et al. Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat. Neuroscience Letters. 2007;414(2):121–125. [PubMed] 45. Vaysse L, Sol JC, Lazorthes Y, Courtade-Saidi M, Eaton MJ, Jozan S. GABAergic pathway in a rat model of chronic neuropathic pain: modulation after intrathecal transplantation of a human neuronal cell line. Neuroscience Research. 2011;69(2):111–120. [PubMed] 46. Eaton MJ, Pearse DD, McBroom JS, Berrocal YA. The combination of human neuronal serotonergic cell implants and environmental enrichment after contusive SCI improves motor recovery over each individual strategy. Behavioural Brain Research. 2008;194(2):236–241. [PubMed]
47. Eaton MJ, Widerström-Noga E, Wolfe SQ. Subarachnoid transplant of a human neuronal serotonergic cell line attenuates chronic allodynia and hyperalgesia without affecting motor dysfunction after severe contusive spinal cord injury. Neurology Research International. 2011;2011:24 pages. Article ID 891605.
48. Cheung WMW, Fu WY, Hui WS, Ip NY. Production of human CNS neurons from embryonal carcinoma cells using a cell aggregation method. BioTechniques. 1999;26(5):946–954. [PubMed] 49. Zhang A-L, Hao J-X, Seiger A, et al. Decreased GABA immunoreactivity in spinal cord dorsal horn neurons after transient spinal cord ischemia in the rat. Brain Research. 1994;656(1):187–190. [PubMed] 50. Saporta S, Willing AE, Colina LO, et al.
In vitro and in vivo characterization of hNT neuron neurotransmitter phenotypes. Brain Research Bulletin. 2000;53(3):263–268. [PubMed] 51. Woehrling EK, Hill EJ, Coleman MD. Development of a neurotoxicity test-system, using human post-mitotic, astrocytic and neuronal cell lines in co-culture. Toxicology in Vitro. 2007;21(7):1241–1246. [PubMed] 52. White LA, Eaton MJ, Castro MC, et al. Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons. Journal of Neuroscience I. 1994;14(11):6744–6753. [PubMed] 53. Bennett GJ, Xie Y-K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain. 1988;33(1):87–107. [PubMed] 54. Hama AT, Sagen J. Reduced pain-related behavior by adrenal medullary transplants in rats with experimental painful peripheral neuropathy. Pain. 1993;52(2):223–231. [PubMed] 55. Brewer KL, Yezierski RP. Effects of adrenal medullary transplants on pain-related behaviors following excitotoxic spinal cord injury. Brain Research. 1998;798(1-2):83–92. [PubMed] 56. Gruner JA. A monitored contusion model of spinal cord injury in the rat. Journal of Neurotrauma. 1992;9(2):123–128. [PubMed] 57. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods. 1994;53(1):55–63. [PubMed] 58. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988;32(1):77–88. [PubMed] 59. Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. Journal of Neurotrauma. 1995;12(1):1–21. [PubMed] 60. Popovich PG, Guan Z, Wei P, Huitinga I, van Rooijen N, Stokes BT. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Experimental Neurology. 1999;158(2):351–365. [PubMed] 61. Eaton MJ, Wolfe SQ. Clinical feasibility for cell therapy utilizing a human neuronal cell line to treat neuropathic pain-like behaviors following SCI in the rat. Journal of Rehabilitation Research & Development. 2009;46(1):145–166. [PubMed] 62. Spinella MJ, Kitareewan S, Mellado B, Sekula D, Khoo KS, Dmitrovsky E. Specific retinoid receptors cooperate to signal growth suppression and maturation of human embryonal carcinoma cells. Oncogene. 1998;16(26):3471–3480. [PubMed] 63. Dmitrovsky E, Moy D, Miller WH, Li A, Masui H. Retinoic acid causes a decline in TGF-alpha expression, cloning efficiency, and tumorigenicity in a human embryonal cancer cell line. Oncogene Research. 1990;5(3):233–239. [PubMed] 64. Marsala M, Kakinohana O, Yaksh TL, Tomori Z, Marsala S, Cizkova D. Spinal implantation of hNT neurons and neuronal precursors: graft survival and functional effects in rats with ischemic spastic paraplegia. European Journal of Neuroscience. 2004;20(9):2401–2414. [PubMed] 65. Nelson PT, Kondziolka D, Wechsler L, et al. Clonal human (hNT) neuron grafts for stroke therapy: neuropathology in a patient 27 months after implantation. American Journal of Pathology. 2002;160(4):1201–1206. [PubMed] 66. Stilley CS, Ryan CM, Kondziolka D, Bender A, de Cesare S, Wechsler L. Changes in cognitive function after neuronal cell transplantation for basal ganglia stroke. Neurology. 2004;63(7):1320–1322. [PubMed] 67. Kondziolka D, Wechsler L, Gebel J, de Cesare S, Elder E, Meltzer CC. Neuronal transplantation for motor stroke: from the laboratory to the clinic. Physical Medicine and Rehabilitation Clinics of North America. 2003;14(1):S153–S160. [PubMed] 68. Yond VW, Kim SU. A new double labelling immunofluorescence technique for the determination of proliferation of human astrocytes in culture. Journal of Neuroscience Methods. 1987;21(1):9–16. [PubMed] 69. Brown DB, Stanfield BB. The use of bromodeoxyuridine-immunohistochemistry to identify transplanted fetal brain tissue. Journal of Neural Transplantation. 1989;1(3-4):135–139. [PMC free article] [PubMed] 70. Lariviere WR, Melzack R. The bee venom test: a new tonic-pain test. Pain. 1996;66(2-3):271–277. [PubMed] 71. Sima AAF, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia. 1999;42(7):773–788. [PubMed] 72. Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80(1-2):391–398. [PubMed] 73. Eaton MJ, Herman JP, Potter E, et al. Immortalized chromaffin cells disimmortalized with Cre/lox site-directed recombination effective in cell therapy for pain. Society for Neuroscience. 2000;26:p. 1622. [PubMed] 74. Eaton MJ, Martinez MA, Karmally S. A single intrathecal injection of GABA permanently reverses neuropathic pain after nerve injury. Brain Research. 1999;835(2):334–339. [PubMed] 75. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(12, supplement 9):S17–S25. [PubMed] 76. Wu SC, Wrobel JS, Armstrong DG. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia. pain Medicine. 2007;8(supplement 2):S33–S42. [PubMed] 77. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews. 2009;(3) Article ID CD007076. [PubMed]
78. Yezierski RP, Liu S, Ruenes GL, et al. Behavioral and pathological characteristics of a central pain model following spinal injury. In: Proceedings of the 8th World Congress on pain; August 1996; British Columbia, Canada .
79. Lindsey AE, LoVerso RL, Tovar CA, Hill CE, Beattie MS, Bresnahan JC. An analysis of changes in sensory thresholds to mild tactile and cold stimuli after experimental spinal cord injury in the rat. Neurorehabilitation and Neural Repair. 2000;14(4):287–300. [PubMed] 80. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Experimental Neurology. 1996;139(2):244–256. [PubMed] 81. Pearse DD, Bunge MB. Paralysis research: promoting nerve fiber protection, growth and functional recovery by cyclic AMP and cell transplantation. Discovery Medicine. 2004;4(22):199–202. [PubMed] 82. Megiorni F, Mora B, Indovina P, Mazzilli MC. Expression of neuronal markers during NTera2/cloneD1 differentiation by cell aggregation method. Neuroscience Letters. 2005;373(2):105–109. [PubMed] 83. Pleasure SJ, Page C, Lee VMY. Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons. Journal of Neuroscience. 1992;12(5):1802–1815. [PubMed] 84. Usvald D, Vodicka P, Hlucilova J, et al. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplantation. 2010;19(9):1103–1122. [PubMed] 85. Guillemain I, Alonso G, Patey G, Privat A, Chaudieu I. Human NT2 neurons express a large variety of neurotransmission phenotypes in vitro. Journal of Comparative Neurology. 2000;422(3):380–395. [PubMed] 86. Podrygajlo G, Tegenge MA, Gierse A, et al. Cellular phenotypes of human model neurons (NT2) after differentiation in aggregate culture. Cell and Tissue Research. 2009;336(3):439–452. [PubMed] 87. Alenina N, Bashammakh S, Bader M. Specification and differentiation of serotonergic neurons. Stem Cell Reviews. 2006;2(1):5–10. [PubMed] 88. Berninger B, Guillemot F, Götz M. Directing neurotransmitter identity of neurones derived from expanded adult neural stem cells. European Journal of Neuroscience. 2007;25(9):2581–2590. [PubMed] 89. Wang B, Zou X, Zhang H, et al. Establishment of an immortalized GABAergic neuronal progenitor cell line from embryonic ventral mesencephalon in the rat. Brain Research. 2008;1210:63–75. [PubMed] 90. Gokhan S, Song Q, Mehler MF. Generation and regulation of developing immortalized neural cell lines. Methods. 1998;16(3):345–358. [PubMed] 91. Eaton MJ, Staley JK, Globus MYY, Whittemore SR. Developmental regulation of early serotonergic neuronal differentiation: the role of brain-derived neurotrophic factor and membrane depolarization. Developmental Biology. 1995;170(1):169–182. [PubMed] 92. Eaton MJ, Whittemore SR. ACTH activation of adenylate cyclase in raphe neurons: multiple regulatory pathways control serotonergic neuronal differentiation. Journal of Neurobiology. 1995;28(4):465–481. [PubMed] 93. Rudge JS, Eaton MJ, Mather P, Lindsay RM, Whittemore SR. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro. Molecular and Cellular Neurosciences. 1996;7(3):204–221. [PubMed] 94. Eaton MJ, Frydel B, Lopez T, et al. Generation and initial characterization of conditionally immortalized chromaffin cells. Journal of Cellular Biochemistry. 2000;79(1):38–57. [PubMed] 95. Hains BC, Johnson KM, McAdoo DJ, et al. Engraftment of immortalized serotonergic neurons enhances locomotor function and attenuates pain-like behavior following spinal hemisection injury in the rat. Experimental Neurology. 2001;171(2):361–378. [PubMed] 96. Hains BC, Johnson KM, Eaton MJ, Willis WD, Hulsebosch CE. Serotonergic neural precursor cell grafts attenuate bilateral hyperexcitability of dorsal horn neurons after spinal hemisection in rat. Neuroscience. 2003;116(4):1097–1110. [PubMed] 97. Duplan H, Li RY, Vue C, et al. Grafts of immortalized chromaffin cells bio-engineered to improve met-enkephalin release also reduce formalin-evoked c-fos expression in rat spinal cord. Neuroscience Letters. 2004;370(1):1–6. [PubMed]
98. Eaton MJ, Vaysse L, Herman JP, et al. Creation of immortalized chromaffin cell lines for clinical applications. IRPCA Advances and Research Updates. 2007;9(1):13–26.
99. Sagen J. Cellular therapies for spinal cord injury: what will the FDA need to approve moving from the laboratory to the human? Journal of Rehabilitation Research and Development. 2003;40(supplement 1):71–79. [PubMed] 100. Ditto AJ, Shah PN, Yun YH. Non-viral gene delivery using nanoparticles. Expert Opinion on Drug Delivery. 2010;6(11):1149–1160. [PubMed] 101. Hartley RS, Margulis M, Fishman PS, et al. Functional synapses are formed betweeen human NTera2 (NT2N, hNT) neurons grown on astrocytes. The Journal of Comparative Neurology. 1999;407(1):1–10. [PubMed] 102. Soprano DR, Teets BW, Soprano KJ. Role of retinoic acid in the differentiation of embryonal carcinoma and embryonic stem cells. Vitamins and Hormones. 2007;75:69–95. [PubMed] 103. Cheung WM, Chu AH, Ip NY. Indentification of candidate genes induced by retinoic acid in embryonal carcinoma cells. Journal of Neurochemistry. 1997;68(5):1882–1888. [PubMed] 104. Baselga J, Maerz WJ, Moy D, et al. Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell. Oncogene. 1993;8(12):3257–3263. [PubMed] 105. Baldassarre G, Boccia A, Bruni P, et al. Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth and Differentiation. 2000;11(10):517–526. [PubMed] 106. Curtin JC, Dragnev KH, Sekula D, Christie AJ, Dmitrovsky E, Spinella MJ. Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. Oncogene. 2001;20(20):2559–2569. [PubMed] 107. Fang H, Chartier J, Sodja C, et al. Transcriptional activation of the human brain-derived neurotrophic factor gene promoter III by dopamine signaling in NT2/N neurons. Journal of Biological Chemistry. 2003;278(29):26401–26409. [PubMed] 108. Miyazono M, Lee VMY, Trojanowski JQ. Proliferation, cell death, and neuronal differentiation in transplanted human embryonal carcinoma (NTera2) cells depend on the graft site in nude and severe combined immunodeficient mice. Laboratory Investigation. 1995;73(2):273–283. [PubMed] 109. Lazorthes Y, Sagen J, Sallerin B, et al. Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain. 2000;87(1):19–32. [PubMed] 110. Bakay RAE, Boyer KL, Freed CR, Ansari AA. Immunological responses to injury and grafting in the central nervous system of nonhuman primates. Cell Transplantation. 1998;7(2):109–120. [PubMed] 111. Barrett AJ, Rezvani K, Solomon S, et al. New developments in allotransplant immunology. Hematology. 2003:350–371. [PubMed] 112. Hori J, Ng TF, Shatos M, Klassen H, Streilein JW, Young MJ. Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells. 2003;21(4):405–416. [PubMed] 113. Stubley LA, Martinez MA, Karmally S, Lopez T, Cejas P, Eaton MJ. Only early intervention with gamma-aminobutyric acid cell therapy is able to reverse neuropathic pain after partial nerve injury. Journal of Neurotrauma. 2001;18(4):471–477. [PubMed] 114. Schott GD. Delayed onset and resolution of pain. Some observations and implications. Brain. 2001;124, part 6:1067–1076. [PubMed] 115. Sharma U, Griesing T, Emir B, Young JP. Time to onset of neuropathic pain reduction: a retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. American Journal of Therapeutics. 2010;17(6):577–585. [PubMed] 116. Hentall ID, Sagen J. The alleviation of pain by cell transplantation. Progress in Brain Research. 2000;127:535–550. [PubMed] 117. Bhattacharya N, Chhetri MK, Mukherjee KL, et al. Human fetal adrenal transplant: a possible role in relieving intractable pain in advanced rheumatoid arthritis. Clinical & Experimental Obstetrics & Gynecology. 2002;29(3):197–206. [PubMed] 118. Hains BC, Chastain KM, Everhart AW, McAdoo DJ, Hulsebosch CE. Transplants of adrenal medullary chromaffin cells reduce forelimb and hindlimb allodynia in a rodent model of chronic central pain after spinal cord hemisection injury. Experimental Neurology. 2000;164(2):426–437. [PubMed] 119. Eaton MJ, Martinez M, Karmally S, Lopez T, Sagen J. Initial characterization of the transplant of immortalized chromaffin cells for the attenuation of chronic neuropathic pain. Cell Transplantation. 2000;9(5):637–656. [PubMed]
120. Eaton MJ. Development of human cell therapy for functional recovery following SCI. The Journal of Spinal Cord Medicine. 2004;27:p. 155.
121. Kim YM, Kwak KH, Lim JO, Baek WY. Reduction of allodynia by intrathecal transplantation of microencapsulated porcine chromaffin cells. Artificial Organs. 2009;33(3):240–249. [PubMed] 122. Ning GZ, Yu TQ, Feng SQ, et al. Epidemiology of traumatic spinal cord injury in Tianjin, China. Spinal Cord. 2010;49(3):386–390. [PubMed] 123. Modirian E, Pirouzi P, Soroush M, Karbalaei-Esmaeili S, Shojaei H, Zamani H. Chronic pain after spinal cord injury: results of a long-term study. pain Medicine. 2010;11(7):1037–1043. [PubMed] 124. Dalyan M, Cardenas DD, Gerard B. Upper extremity pain after spinal cord injury. Spinal Cord. 1999;37(3):191–195. [PubMed]
125. Bennett GJ. Chronic pain due to peripheral nerve damage: an overview. In: Fields HL, Liebeskind JC, editors. Pharmacological Approaches to the Treatment of Chronic pain: New Concepts and Critical Issues. Seattle, Wash, USA: IASP Press; 1994. pp. 51–60.
126. Yezierski RP, Liu S, Ruenes GL, Kajander KJ, Brewer KL. Excitotoxic spinal cord injury: behavioral and morphological characteristics of a central pain model. Pain. 1998;75(1):141–155. [PubMed] 127. Yu CG, Fairbanks CA, Wilcox GL, Yezierski RP. Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. Pain. 2003;4(3):129–140. [PubMed]
128. Hains BC, Bennett AD, Eaton MJ, et al. Intralesion transplantation of serotonin- and BDNF-secreting cells promotes recovery of locomotor function after spinal hemisection injury. Society for Neuroscience. 2001;27:p. 2039.
129. Berrocal Y, Pearse DD, Singh A, et al. Social and environmental enrichment improves sensory and motor recovery after severe contusive spinal cord injury in the rat. Journal of Neurotrauma. 2007;24(11):1761–1772. [PubMed] 130. Novak CB, Katz J. Neuropathic pain in patients with upper-extremity nerve injury. Physiotherapy Canada. 2010;62(3):190–201. [PMC free article] [PubMed] 131. Chong MS, Hester J. Diabetic painful neuropathy: current and future treatment options. Drugs. 2007;67(4):569–585. [PubMed] 132. Hwang JH, Yaksh TL. The effect of spinal GABA receptor agonists on tactile allodynia in a surgically-induced neuropathic pain model in the rat. Pain. 1997;70(1):15–22. [PubMed]
133. Wolfe SQ, Holohean AM, Martinez M, et al. Intrathecal transplant of the human neuronal GABA/glycinergic hNT2.17 cell line for the alleviation of neuropathic pain in the streptozotocin (STZ) model of diabetic neuropathy. Neurosurgery. 2008;62(6):p. 1427.
134. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics. 2009;6(4):638–647. [PubMed] 135. Calcutt NA. Potential mechanisms of neuropathic pain in diabetes. International Review of Neurobiology. 2002;50:205–228. [PubMed] 136. Remuzzi A, Cornolti R, Bianchi R, et al. Regression of diabetic complications by islet transplantation in the rat. Diabetologia. 2009;52(12):2653–2661. [PubMed] 137. Speight J, Reaney MD, Woodcock AJ, Smith RM, Shaw JAM. Patient-reported outcomes following islet cell or pancreas transplantation (alone or after kidney) in Type 1 diabetes: a systematic review. Diabetic Medicine. 2010;27(7):812–822. [PubMed] 138. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Annals of Neurology. 2010;67(4):534–541. [PMC free article] [PubMed] 139. Mittal M, Pasnoor M, Mummaneni RB, et al. Retrospective chart review of duloxetine and pregabalin in the treatment of painful neuropathy. International Journal of Neuroscience. 2011;121(9):521–527. [PubMed] 140. Guastella V, Mick G. Strategies for the diagnosis and treatment of neuropathic pain secondary to diabetic peripheral sensory polyneuropathy. Diabetes and Metabolism. 2009;35(1):12–19. [PubMed] 141. Heeg S, Doebele M, von Werder A, Opitz OG. In vitro transformation models: modeling human cancer. Cell Cycle. 2006;5(6):630–634. [PubMed] 142. Wolfe SQ, Cumberbatch N, Menendez I, Martinez M, Eaton M. Intrathecal transplantation of a human neuronal cell line for the treatment of neuropathic pain in a spinal cord injury model. Clinical neurosurgery. 2007;54:220–225. [PubMed] 143. Brumley MR, Hentall ID, Pinzon A, et al. Serotonin concentrations in the lumbosacral spinal cord of the adult rat following microinjection or dorsal surface application. Journal of Neurophysiology. 2007;98(3):1440–1450. [PMC free article] [PubMed] 144. Majczyński H, Maleszak K, Cabaj A, Sławińska U. Serotonin-related enhancement of recovery of hind limb motor functions in spinal rats after grafting of embryonic raphe nuclei. Journal of Neurotrauma. 2005;22(5):590–604. [PubMed] 145. Feraboli-Lohnherr D, Orsal D, Yakovleff A, Giménez Y Ribotta M, Privat A. Recovery of locomotor activity in the adult chronic spinal rat after sublesional transplantation of embryonic nervous cells: specific role of serotonergic neurons. Experimental Brain Research. 1997;113(3):443–454. [PubMed] 146. Hains BC, Yucra JA, Eaton MJ, Hulsebosch CE. Intralesion transplantation of serotonergic precursors enhances locomotor recovery but has no effect on development of chronic central pain following hemisection injury in rats. Neuroscience Letters. 2002;324(3):222–226. [PubMed]
147. Cardenas DD, Turner JA, Warms CA. Inter-rater reliability of a pain classification system for spinal cord injury. Journal of Spinal Cord Medicine. 2001;24:p. S20.
148. Hains BC, Fullwood SD, Eaton MJ, Hulsebosch CE. Subdural engraftment of serotonergic neurons following spinal hemisection restores spinal serotonin, downregulates serotonin transporter, and increases BDNF tissue content in rat. Brain Research. 2001;913(1):35–46. [PubMed] 149. Todd AJ, McKenzie J. GABA-immunoreactive neurons in the dorsal horn of the rat spinal cord. Neuroscience. 1989;31(3):799–806. [PubMed] 150. Desarmenien M, Feltz P, Occhipinti G. Coexistence of GABA(A) and GABA(B) receptors on Ad and C primary afferents. British Journal of Pharmacology. 1984;81(2):327–333. [PubMed] 151. Malcangio M, Bowery NG. GABA and its receptors in the spinal cord. Trends in Pharmacological Sciences. 1996;17(12):457–462. [PubMed] 152. Sieghart W. GABA-A receptors: ligand-gated Cl- channels modulated by multiple drug-binding sites. Trends in Pharmacological Sciences. 1992;72:169–179. [PubMed]
153. Hulsebosch CE, Christensen MD, Peng YB, et al. Central sensitization of wide dynamic range neurons in chronic central pain after spinal cord hemisection. American pain Society. 1995;95812
154. Yezierski RP, Santana M, Park SH, Madsen PW. Neuronal degeneration and spinal cavitation following intraspinal injections of quisqualic acid in the rat. Journal of Neurotrauma. 1993;10(4):445–456. [PubMed]
155. Stiller CO, Cui JG, O’Connor WT, et al. GABA-ergic mechanisms may be involved in the spinal cord stimulation induced reversion of allodynia: animal studies with microdialysis. American pain Society. 1995;95:p. 801.
156. Kingery WS, Fields RD, Kocsis JD. Diminished dorsal root GABA sensitivity following chronic peripheral nerve injury. Experimental Neurology. 1988;100(3):478–490. [PubMed] 157. Meisner JG, Marsh AD, Marsh DR. Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury. Journal of Neurotrauma. 2010;27(4):729–737. [PubMed] 158. Kjaer M, Nielsen H. The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study. British Journal of Clinical Pharmacology. 1983;16(5):477–485. [PubMed] 159. Gwak YS, Tan HY, Nam TS, Paik KS, Hulsebosch CE, Leem JW. Activation of spinal GABA receptors attenuates chronic central neuropathic pain after spinal cord injury. Journal of Neurotrauma. 2006;23(7):1111–1124. [PubMed] 160. Enna SJ, McCarson KE. The role of GABA in the mediation and perception of pain. Advances in Pharmacology. 2006;54:1–27. [PubMed] 161. Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J. Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. Neuroscience. 1996;76(3):845–858. [PubMed] 162. Yamamoto T, Yaksh TL. Effects of intrathecal strychnine and bicuculline on nerve compression-induced thermal hyperalgesia and selective antagonism by MK-801. Pain. 1993;54(1):79–84. [PubMed] 163. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50(3):355–363. [PubMed] 164. Linderoth B, Stiller CO, O’Connor WT, et al. An animal model for the study of brain transmitter release in response to spinal cord stimulation in the awake, freely moving rat: preliminary results from the periaqueductal grey matter. Acta Neurochirurgica Supplementum. 1993;58:156–160. [PubMed] 165. Thomas DA, Navarrete IM, Graham BA, McGowan MK, Hammond DL. Antinociception produced by systemic R(+)-baclofen hydrochloride is attenuated by CGP 35348 administered to the spinal cord or ventromedial medulla of rats. Brain Research. 1996;718(1-2):129–137. [PubMed] 166. Xu X-J, Hao J-X, Aldskogius H, Seiger A, Wiesenfeld-Hallin Z. Chronic pain-related syndrome in rats after ischemic spinal cord lesion: a possible animal model for pain in patients with spinal cord injury. Pain. 1992;48(2):279–290. [PubMed] 167. Moore KA, Kohno T, Karchewski LA, Scholz J, Baba H, Woolf CJ. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. Journal of Neuroscience. 2002;22(15):6724–6731. [PubMed] 168. Polgár E, Todd AJ. Tactile allodynia can occur in the spared nerve injury model in the rat without selective loss of GABA or GABAA receptors from synapses in laminae I-II of the ipsilateral spinal dorsal horn. Neuroscience. 2008;156(1):193–202. [PMC free article] [PubMed] 169. Polgár E, Hughes DI, Riddell JS, Maxwell DJ, Puskár Z, Todd AJ. Selective loss of spinal GABAergic or glycinergic neurons is not necessary for development of thermal hyperalgesia in the chronic constriction injury model of neuropathic pain. Pain. 2003;104(1-2):229–239. [PubMed] 170. Engle MP, Gassman M, Sykes KT, Bettler B, Hammond DL. Spinal nerve ligation does not alter the expression or function of GABAB receptors in spinal cord and dorsal root ganglia of the rat. Neuroscience. 2006;138(4):1277–1287. [PMC free article] [PubMed] 171. Eaton MJ, Plunkett JA, Martinez MA, et al. Changes in GAD and GABA immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic neurons. Journal of Chemical Neuroanatomy. 1998;16(1):57–72. [PubMed] 172. Feldblum S, Dumoulin A, Anoal M, et al. Comparative distribution of GAD65 and GAD67 mRNAs and proteins in the rat spinal cord supports a differential regulation of these two glutamate decarboxylases in vivo. Journal of Neuroscience Research. 1995;42(6):742–757. [PubMed] 173. Rimvall K, Martin DL. The level of GAD67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. Journal of Neurochemistry. 1994;62(4):1375–1381. [PubMed] 174. Rimvall K, Sheikh SN, Martin DL. Effects of increased gamma-aminobutyric acid levels on GAD67 protein and mRNA levels in rat cerebral cortx. Journal of Neurochemistry. 1993;60(2):714–720. [PubMed]
175. Towers S, Bowery N, Bettler B, et al. GBR mRNAs and GABA-B binding in the spinal cord and dorsal root ganglia during chronic pain. Society for Neuroscience. In press.
176. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. American Journal of Medicine. 1999;107(2) [PubMed] 177. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin- dependent diabetes mellitus. New England Journal of Medicine. 1995;333(2):89–94. [PubMed] 178. Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycemic control. Diabetes Research and Clinical Practice. 2002;57(1):45–51. [PubMed] 179. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Research and Clinical Practice. 2000;47(2):123–128. [PubMed] 180. Otto M, Bak S, Bach FW, Jensen TS, Sindrup SH. Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain. 2003;101(1-2):187–192. [PubMed] 181. Corbett CF. Practical management of patients with painful diabetic neuropathy. Diabetes Educator. 2005;31(4):523–540. [PubMed] 182. Hasegawa T, Kosaki A, Shimizu K, et al. Amelioration of diabetic peripheral neuropathy by implantation of hematopoietic mononuclear cells in streptozotocin-induced diabetic rats. Experimental Neurology. 2006;199(2):274–280. [PubMed]
183. Besson JM, Chaouch A. Descending serotonergic systems. In: Akil H, Lewis JW, editors. Neurotransmitters and pain Control. New York, NY, USA: Karger; 1987. pp. 64–100.
184. Akil H, Liebeskind JC. Monoaminergic mechanisms of stimulation produced analgesia. Brain Research. 1975;94(2):279–296. [PubMed] 185. Jones SL. Descending noradrenergic influences on pain. Progress in Brain Research. 1991;88:381–394. [PubMed] 186. Bowker RM, Westlund KN, Coulter JD. Origins of serotonergic projections to the lumbar spinal cord in the monkey using a combined retrograde transport and immunocytochemical technique. Brain Research Bulletin. 1982;9(1–6):271–278. [PubMed] 187. Marlier L, Sandillon F, Poulat P, et al. Serotonergic innervation of the dorsal rat spinal cord: light and electron microscopic immunocytochemistry study. Journal of Neurocytology. 1991;20(4):310–322. [PubMed] 188. Skagerberg G, Bjorklund A. Response properties of upper cervical spinothalamic neurons in cats: a possible explanation for the unusual sensory symptoms associated with upper cervical lesions in humans. Neuroscience. 1985;15:445–480. [PubMed]
189. Fields HL, Basbaum AI. Endogenous pain control mechanisms. In: Wall PD, Melzack R, editors. Textbook of Pain. London, UK: Churchill Livingston; 1984. pp. 142–152.
190. Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception. Physiological Reviews. 1987;67(1):67–186. [PubMed] 191. Sanchez A, Niedbala B, Feria M. Modulation of neuropathic pain in rats by intrathecally injected serotonergic agonists. NeuroReport. 1995;6(18):2585–2588. [PubMed] 192. Solomon RE, Gebhart GF. Mechanisms of effects of intrathecal serotonin on nociception and blood pressure in rats. Journal of Pharmacology and Experimental Therapeutics. 1988;245(3):905–912. [PubMed] 193. Yaksh TL, Wilson PR. Spinal serotonin terminal system mediates antinociception. Journal of Pharmacology and Experimental Therapeutics. 1979;208(3):446–453. [PubMed] 194. Willcockson WS, Chung JM, Hori Y. Effects of iontophoretically released amino acids and amines on primate spinothalamic tract cells. Journal of Neuroscience. 1984;4(3):732–740. [PubMed] 195. Shapiro S. Neurotransmission by neurons that use serotonin, noradrenaline, glutamate, glycine, and gamma-aminobutyric acid in the normal and injured spinal cord. Neurosurgery. 1997;40(1):168–176. [PubMed] 196. Zhang B, Goldberger ME, Murray M. Proliferation of SP- and 5HT-containing terminals in lamina II of rat spinal cord following dorsal rhizotomy: quantitative EM-immunocytochemial studies. Experimental Neurology. 1993;123(1):51–63. [PubMed] 197. Hains BC, Everhart AW, Fullwood SD, Hulsebosch CE. Changes in serotonin, serotonin transporter expression and serotonin denervation supersensitivity: involvement in chronic central pain after spinal hemisection in the rat. Experimental Neurology. 2002;175(2):347–362. [PubMed] 198. Hains BC, Willis WD, Hulsebosch CE. Serotonin receptors 5-HT1A and 5-HT3 reduce hyperexcitability of dorsal horn neurons after chronic spinal cord hemisection injury in rat. Experimental Brain Research. 2003;149(2):174–186. [PubMed] 199. Bruce JC, Oatway MA, Weaver LC. Chronic pain after clip-compression injury of the rat spinal cord. Experimental Neurology. 2002;178(1):33–48. [PubMed] 200. Faden AI, Gannon A, Basbaum AI. Use of serotonin immunocytochemistry as a marker of injury severity after experimental spinal trauma in rats. Brain Research. 1988;450(1-2):94–100. [PubMed] 201. Fong AJ, Cai LL, Otoshi CK, et al. Spinal cord-transected mice learn to step in response to quipazine treatment and robotic training. Journal of Neuroscience. 2005;25(50):11738–11747. [PubMed] 202. Berger AJ, Bayliss DA, Viana F. Modulation of neonatal rat hypoglossal motoneuron excitability by serotonin. Neuroscience Letters. 1992;143(1-2):164–168. [PubMed]
203. Rossignol S, Lund JP, Drew T. The role of sensory inputs in regulating patterns of rhythmical movements in higher vertebrates. A comparison between locomotion, respiration and mastication. In: Cohen AH, Rossignol S, Grillner S, editors. Neural Control of Rhythmic Movements in Vertebrates. New York, NY, USA: Wiley; 1988. pp. 201–283.
204. Slawinska U, Majczynski H, Djavadian R. Recovery of hindlimb motor functions after spinal cord transection is enhanced by grafts of embryonic raphe nuclei. Experimental Brain Research. 2000;132(1):27–38. [PubMed] 205. White SR, Neuman RS. Facilitation of spinal motoneuron excitability by 5-hydroxytryptamine and noradrenaline. Brain Research. 1980;188(1):119–127. [PubMed] 206. Stamford JA. Descending control of pain. British Journal of Anaesthesia. 1995;75(2):217–227. [PubMed] 207. Borlongan CV, McWhirter C, Fultz-Carver C, et al. The case for an ethics research consortium for emerging technologies: public perception of stem cell research and development. Technology & Innovation. 2010;12(1):21–28. [PMC free article] [PubMed]